# Daclatasvir

## Daklinza 60mg

| 藥物代碼 | ODAK |
| :--- | :--- |
| 適應症 | Chronic hepatitis C: Treatment of chronic hepatitis C virus \(HCV\) genotype 1 or genotype 3 infection in combination with sofosbuvir, with or without ribavirin |
| 副作用 | &gt;10%:Central nervous system: Fatigue \(14% to 15%\), headache \(12% to 14%\)Gastrointestinal: Nausea \(8% to 15%\)Hematologic & Oncologic: Anemia \(20%\)1~10%Central nervous system: Drowsiness \(5%\), insomnia \(3%\)Dermatologic: Skin rash \(8%\)Gastrointestinal: Diarrhea \(3% to 5%\), increased serum lipase \(&gt;3x ULN, transient\) |
| 禁忌 | Concurrent use of strong CYP3A inducers \(eg, carbamazepine, phenytoin, rifampin, St John's wort\). When used in combination with other agents \(eg, ribavirin\), the contraindications to those agents also apply \(refer to respective labeling information\). |
| 藥物保存方式 | N/A |
| 用法用量 | Chronic hepatitis C \(genotype 1 or 3\): Oral: Note: Discontinue daclatasvir if sofosbuvir is permanently discontinued. Genotype 1:Without cirrhosis or with compensated \(Child-Pugh class A\) cirrhosis: 60 mg once daily with concomitant sofosbuvir for 24 weeks. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity\(Mother\) 無\(很少\)資料 - 避免使用\(母體\) |
| 附帶說明 | 以上懷孕及哺乳分級參考資料來源為藥品仿單 |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

